Learning

April 5, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA BANCR increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 5/April/2019, 11.07 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
April 2, 2019

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA AK027294 inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 2/April/2019, 6.50 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
April 1, 2019

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA 00152   inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 1/April/2019, 11,51 pm

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
March 31, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]